乌帕替尼单药治疗改善类风湿关节炎患者报告结局:SELECT-EARLY与SELECT-MONOTHERAPY研究结果
两项随机对照试验评估乌帕替尼单药对比甲氨蝶呤对类风湿关节炎患者报告结局的影响,纳入945例未经甲氨蝶呤治疗和648例甲氨蝶呤反应不足患者,乌帕替尼15mg或30mg单药治疗12/14周在疼痛、躯体功能、晨僵、健康相关生活质量和工作生产力方面较甲氨蝶呤显著改善。
要点
- 乌帕替尼单药治疗较甲氨蝶呤显著改善患者报告结局。
- 改善在治疗第2周即可观察到。
- 更多乌帕替尼治疗患者达到最小临床重要差异和正常值。
核心结论
- 在未经甲氨蝶呤治疗和甲氨蝶呤反应不足的活动性类风湿关节炎患者中,乌帕替尼15mg或30mg单药治疗12/14周较甲氨蝶呤单药在疼痛、躯体功能、晨僵、健康相关生活质量和工作生产力方面产生统计学显著且临床有意义的改善。
研究设计与样本
- 基于SELECT-EARLY和SELECT-MONOTHERAPY两项随机对照试验的患者报告结局数据,在笫2周和第12/14周进行评估;患者年龄≥18岁,类风湿关节炎症状≥6周(SELECT-EARLY,未经甲氨蝶呤治疗)或诊断为类风湿关节炎≥3个月(SELECT-MONOTHERAPY,甲氨蝶呤反应不足),接受乌帕替尼单药(15或30mg)或甲氨蝶呤治疗。
主要发现
- 在945例未经甲氨蝶呤治疗和648例甲氨蝶呤反应不足患者中,乌帕替尼(15mg、30mg)单药对比甲氨蝶呤在第12/14周时患者整体疾病活动度评估、疼痛、HAQ-DI、晨僵持续时间/严重程度、FACIT-疲劳(SELECT-EARLY)、健康相关生活质量和WPAI(SELECT-EARLY)的基线最小二乘均值变化更大。
- 两项随机对照试验中,第12/14周时两种剂量乌帕替尼对比甲氨蝶呤的这些变化均具有统计学显著性。
- 改善早在第2周即有报告。
- 与甲氨蝶呤相比,更多乌帕替尼治疗的未经甲氨蝶呤治疗和甲氨蝶呤反应不足患者报告达到大于或等于最小临床重要差异的改善以及大于或等于正常值的评分。
关键数值与推荐
- 乌帕替尼单药剂量为15mg或30mg,评估时间点为第2周和第12/14周。
- 患者报告结局包括患者整体疾病活动度评估、疼痛视觉模拟量表、HAQ残疾指数、晨僵持续时间/严重程度、FACIT-疲劳(SELECT-EARLY)、36项简表健康调查的健康相关生活质量和WPAI(SELECT-EARLY)。
临床怎么用
- 对于未经甲氨蝶呤治疗或甲氨蝶呤反应不足的活动性类风湿关节炎患者,乌帕替尼15mg或30mg单药治疗可在12/14周内改善患者报告的疼痛、躯体功能、晨僵、健康相关生活质量和工作生产力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the effect of upadacitinib (UPA) monotherapy vs MTX on patient-reported outcomes (PROs) in patients with RA who were MTX-naïve or who had an inadequate response to MTX (MTX-IR). METHODS: PROs from the SELECT-EARLY and SELECT-MONOTHERAPY randomized controlled trials were evaluated at Weeks 2 and 12/14. Patients were ≥18 years of age with RA symptoms for ≥6 weeks (SELECT-EARLY, MTX-naïve) or diagnosed RA for ≥3 months (SELECT-MONOTHERAPY, MTX-IR) and received UPA monotherapy (15 or 30 mg) or MTX. PROs included Patient Global Assessment of Disease Activity (PtGA), pain visual analogue scale, HAQ Disability Index (HAQ-DI), morning stiffness duration/severity, Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue (SELECT-EARLY), health-related quality of life (HRQOL) by the 36-iem Short Form Health Survey and Work Productivity and Activity Impairment (WPAI; SELECT-EARLY). Least square mean (LSM) changes and proportions of patients reporting improvements greater than or equal to the minimum clinically important differences and normative values were determined. RESULTS: In 945 MTX-naïve and 648 MTX-IR patients, UPA monotherapy (15 mg, 30 mg) vs MTX resulted in greater reported LSM changes from baseline at Weeks 12/14 in PtGA, pain, HAQ-DI, morning stiffness duration/severity, FACIT-F (SELECT-EARLY), HRQOL and WPAI (SELECT-EARLY). These changes were statistically significant with both doses of UPA vs MTX at Weeks 12/14 in both RCTs. Improvements were reported as early as week 2. Compared with MTX, more UPA-treated MTX-naïve and MTX-IR patients reported improvements greater than or equal to the minimum clinically important differences and scores greater than or equal to normative values. CONCLUSION: Among MTX-naïve and MTX-IR patients with active RA, UPA monotherapy at 15 or 30 mg for 12/14 weeks resulted in statistically significant and clinically meaningful improvements in pain, physical function, morning stiffness, HRQOL and WPAI compared with MTX alone. CLINICAL TRIAL REGISTRATION NUMBER: SELECT-EARLY (NCT02706873) and SELECT-MONOTHERAPY (NCT02706951) are registered with ClinicalTrials.gov.
引用
- Strand V, Tundia N, Wells A, et al. Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY. Rheumatology (Oxford). 2021. PMID: 33313898. doi:10.1093/rheumatology/keaa770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。